CoChat

Antidepressant Efficacy for Depression in Children and Adolescents: Industry- and NIMH-Funded Studies

Walkup, John T. · 2017 · American Journal of Psychiatry

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Abstract

Significant controversy surrounds the efficacy of the newer antidepressants for children and adolescents with depression. The controversy largely hinges on meta-analyses of studies that suggest that antidepressants are minimally effective, not effective, or equivalent to placebo. In this review, the author discusses several scientific and clinical complexities that are important to understand in reviewing the antidepressant literature: the strengths and weaknesses of meta-analyses; the scientific and regulatory context for the large number of antidepressant trials in the late 1990s and early 2000s; and the distinction between a negative trial, where the treatment does not demonstrate efficacy, and a failed trial, where methodological problems make it impossible to draw any conclusion about efficacy. It is the premise of this review that meta-analyses that include the large number of industry-sponsored antidepressant trials distort the picture of antidepressant efficacy for teen depression. Industry-sponsored child and adolescent depression trials suffer from a number of implementation challenges and should be considered failed trials that are largely uninformative and not eligible to be included in efficacy meta-analyses. In contrast to the industry-sponsored trials, depression trials funded by the National Institute of Mental Health (NIMH) (N=2) are characterized by many methodological strengths, lower placebo response rates (30%-35%), and meaningful between-group differences (25%-30%) that support antidepressant efficacy. The NIMH-funded trials, taken together with the demonstrated efficacy of the serotonin reuptake inhibitors for childhood-onset obsessive-compulsive disorder and the anxiety disorders, suggest a broad and important role for antidepressant medications in pediatric internalizing conditions.

Overview

Integrity signals

Registry

Crossref · 10.1176/appi.ajp.2017.16091059

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 27 references

Research works printed but not linked: 1

  1. Goodyer IM, 2008, Health Technol Assess, iii

Cited by

See all 120

Metadata

Authors
Walkup, J. T.
Affiliations
Weill Cornell Medicine (US)
Corresponding author
Walkup, John T.
Venue
American Journal of Psychiatry
Published
2017-05-01
Volume
174
Issue
5
Pages
430-437
ISSN
  • 0002-953X (ISSN-L)
  • 1535-7228
OpenAlex
W2593791726
Cited by
112
References
27
Citations by year
2026: 5 · 2025: 10 · 2024: 11 · 2023: 6 · 2022: 16 · 2021: 16 · 2020: 10 · 2019: 11 · 2018: 18 · 2017: 9
FWCI
9.16
Type
journal article
Language
en
Open access
closed
Locations
  • American Journal of Psychiatry (publishedVersion, public-domain)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Social Sciences › Psychology › Clinical Psychology › Child and Adolescent Psychosocial and Emotional Development
  • Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
Keywords
antidepressant efficacy, childhood depression, adolescent depression, industry-sponsored trials, meta-analysis limitations, placebo response, serotonin reuptake inhibitors, obsessive-compulsive disorder, anxiety disorders, internalizing disorders, antidepressant trials
MeSH terms
Adolescent, Antidepressive Agents, Anxiety Disorders, Child, Clinical Trials as Topic, Depressive Disorder, Drug Industry, Financing, Government, Financing, Organized, Humans, National Institute of Mental Health (U.S.), Obsessive-Compulsive Disorder, Research Design, Research Support as Topic, United States, Meta-Analysis as Topic, Treatment Outcome, Treatment Failure, Selective Serotonin Reuptake Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Antidepressant Efficacy for Depression in Children and Adolescents: Industry- and NIMH-Funded Studies. https://app.cochat.ai/papers/10.1176/appi.ajp.2017.16091059
The paper
Walkup, J. T. (2017). Antidepressant Efficacy for Depression in Children and Adolescents: Industry- and NIMH-Funded Studies. American Journal of Psychiatry. https://doi.org/10.1176/appi.ajp.2017.16091059

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.